Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Novartis Japan Chief Vows All-Out Effort to Regain Trust
Novartis Pharma will redouble its efforts to overhaul its corporate culture and internal process in a bid to restore the public trust it has lost due to a spate of clinical trial scandals and side effect reporting problems, President Dirk…
To read the full story
Related Article
- Novartis Eager to See More 1st Approvals in Japan despite Pricing Headache
September 14, 2016
- Novartis Has High Hopes for T-Cell Therapy CTL019
June 10, 2015
BUSINESS
- Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
- Takeda Files Entyvio IV for Pediatric Use, New Adult Dosing in Japan
July 29, 2026
- Otsuka Ups 1H Guidance on Strong Sales, Delayed Generic Competition
July 29, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…